Sarcoma Trials at MSK

Researchers are assessing a new type of therapy in young people with solid tumors that keep growing even after treatment. The therapy is called afamitresgene autoleucel. The people in this study have synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), neuroblastoma, or osteosarcoma. In addition, they have tested positive for the HLA-A*02 gene and their cancers make a protein called MAGE-A4. This protein plays a role in cancer growth.

Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.

Researchers want to find the best dose of DCC-3116 to give with ripretinib for people with gastrointestinal stromal tumor (GIST). The people in this study have GIST that has spread, even with treatment.

Researchers in this study want to find the best dose of lurbinectedin to treat cancer in children and adults. They also want to see how well this drug works. The people in this study have Ewing sarcoma or other solid tumors that keep growing after treatment. In addition, their cancers contain a genetic change called a FET fusion.

Researchers want to find the best dose of GI-102 for treating advanced sarcoma. The people in this study have sarcoma that has spread.

Mirdametinib blocks proteins called MEK1 and MEK2, which play an important role in cancer cell growth and survival. By blocking MEK1 and MEK2, mirdametinib may slow or stop the growth of your cancer.

Pembrolizumab takes the brakes off the immune system so immune cells can find and hopefully attack cancer cells. It is given intravenously (by vein).

Researchers want to see how well tebentafusp works in people with clear cell sarcoma that has spread. This cancer grows deeply into soft tissues of the arms and legs. The people in this study have clear cell sarcoma that is inoperable (cannot be surgically removed) or has spread.

In this study, researchers want to learn if tigilanol tiglate is safe and works well against advanced soft tissue sarcoma. When injected into a tumor, tigilanol tiglate stops the blood supply to the cancer, which starves the tumor of nutrients. It may also make the immune system target and kill cancer cells.

Researchers want to see if adding cabozantinib to standard chemotherapy works better than chemotherapy alone for osteosarcoma. The people in this study include children, adolescents, and young adults with osteosarcoma that has not yet been treated.